- Research article
- Open Access
- Open Peer Review
Targeting the epidermal growth factor receptor in non-small cell lung cancer cells: the effect of combining RNA interference with tyrosine kinase inhibitors or cetuximab
© Chen et al; licensee BioMed Central Ltd. 2012
- Received: 27 November 2011
- Accepted: 21 March 2012
- Published: 21 March 2012
The epidermal growth factor receptor (EGFR) is a validated therapeutic target in non-small cell lung cancer (NSCLC). However, current single agent receptor targeting does not achieve a maximal therapeutic effect, and some mutations confer resistance to current available agents. In the current study we have examined, in different NSCLC cell lines, the combined effect of RNA interference targeting the EGFR mRNA, and inactivation of EGFR signaling using different receptor tyrosine kinase inhibitors (TKIs) or a monoclonal antibody cetuximab.
NSCLC cells (cell lines HCC827, H292, H358, H1650, and H1975) were transfected with EGFR siRNA and/or treated with the TKIs gefitinib, erlotinib, and afatinib, and/or with the monoclonal antibody cetuximab. The reduction of EGFR mRNA expression was measured by real-time quantitative RT-PCR. The down-regulation of EGFR protein expression was measured by western blot, and the proliferation, viability, caspase3/7 activity, and apoptotic morphology were monitored by spectrophotometry, fluorimetry, and fluorescence microscopy. The combined effect of EGFR siRNA and different drugs was evaluated using a combination index.
EGFR-specific siRNA strongly inhibited EGFR protein expression almost equally in all cell lines and inhibited cell growth and induced cell apoptosis in all NSCLC cell lines studied, albeit with a different magnitude. The effects on growth obtained with siRNA was strikingly different from the effects obtained with TKIs. The effects of siRNA probably correlate with the overall oncogenic significance of the receptor, which is only partly inhibited by the TKIs. The cells which showed weak response to TKIs, such as the H1975 cell line containing the T790M resistance mutation, were found to be responsive to siRNA knockdown of EGFR, as were cell lines with downstream TKI resistance mutations. The cell line HCC827, harboring an exon 19 deletion mutation, was more than 10-fold more sensitive to TKI proliferation inhibition and apoptosis induction than any of the other cell lines. Cetuximab alone had no relevant in vitro activity at concentrations obtainable in the clinic. The addition of EGFR siRNA to either TKIs or cetuximab additively enhanced growth inhibition and induction of apoptosis in all five cell lines, independent of the EGFR mutation status (wild-type or sensitizing mutation or resistant mutation). The strongest biological effect was observed when afatinib was combined with an EGFR-specific siRNA.
EGFR knockdown by siRNA further decreases the cell growth of lung cancer cells that are treated with TKIs or cetuximab alone, confirming that single agent drug targeting does not achieve a maximal biological effect. The siRNA inhibits EGFR oncogenic activity that bypasses downstream "resistance" mutations such as KRAS and PTEN. The combined treatment of siRNA and EGFR inhibitory agents is additive. The combination of a potent, irreversible kinase inhibitor such as afatinib, with EGFR-specific siRNAs should be further investigated as a new strategy in the treatment of lung cancer and other EGFR dependent cancers, including those with downstream resistance mutations.
- RNA interference
- tyrosine kinase inhibitors (TKIs)
- anti-EGFR monoclonal antibodies (mAbs)
- lung cancer
Non-small cell lung cancer (NSCLC) comprises 75% to 85% of newly diagnosed lung cancers. Over 70% of NSCLC patients present with advanced disease, and the 5-year survival rate for NSCLC is only 16%. For early-stage or locally-advanced lung cancer, surgery is the most effective treatment, and combined chemotherapy is the standard adjuvant approach. For stage III/IV NSCLC, platinum-based combined chemotherapy is the current standard of care, but with much room for improvement .
In a minority of patients, a mutant epidermal growth factor receptor (EGFR) has become a validated therapeutic target and EGFR tyrosine kinase inhibitors (TKIs) gefitinib and erlotinib are currently the first-line treatment options for these patients [2, 3]. These drugs lead to impressive improvements in progression-free survival (PFS) compared to chemotherapy. However, ultimately these tumors develop resistance to these TKIs through various mechanisms. A frequent mechanism is the emergence of a malignant clone with a second mutation in the EGFR kinase domain, a threonine-to-methionine substitution at amino acid position 790 (T790M) .
The ErbB family includes four related receptor proteins (EGFR/ErbB1/HER1, ErbB2/Neu/HER2, ErbB3/HER3, and ErbB4/HER4). The ErbB family of membrane receptors is a group of transmembrane glycoproteins that consists of an extracellular ligand-binding domain, a transmembrane domain, and an intracellular tyrosine kinase domain mediating signal transduction. The complex EGFR signal transduction pathway involves the RAS/MAPK cascade, phosphatidyl inositol 3-kinase (PI3K), signal transducer and activator of transcription (STAT), and downstream protein kinase C (PKC). Following ligand binding, EGFR can homodimerize or heterodimerize with another member of the ErbB family, causing activation of the intracellular tyrosine kinase domain and receptor transphosphorylation. The newly formed phosphotyrosine residues act as docking sites for various adaptor molecules that consequently activate a number of intracellular signaling cascades, that, in case of constitutive activation of the pathway, leads to cell proliferation, inhibition of apoptosis, angiogenesis, and invasion/metastasis, resulting in tumor growth and progression .
Currently two main anti-EGFR strategies are in clinical use: low-molecular-weight TKIs that compete with ATP for binding to the tyrosine kinase portion of the receptor, and monoclonal antibodies that are directed at the ligand-binding extracellular domain thereby preventing ligand binding, receptor dimerization, and receptor signaling. These two classes of agents have shown solid preclinical and clinical activity in a variety of tumor types .
Among the receptor TKIs, single-agent erlotinib (Tarceva, Genentech, Inc, South San Francisco, CA, USA and OSI Pharmaceuticals Inc., Melville, NY, USA) improves survival in advanced NSCLC patients who progressed after chemotherapy [7–10] and is superior to chemotherapy in the first-line treatment of lung adenocarcinoma with an EGFR mutation in exon 19/21 . The aggregated clinical experience today indicates that only patients whose tumors contain a sensitizing mutation in the EGFR tyrosine kinase domain derive an important and meaningful clinical benefit from these agents. Some randomized studies indicate that in patients not selected for such mutations these drugs might even have an adverse effect on outcome . In an unselected patient population, gefitinib maintenance therapy also failed to show a survival advantage .
Not all patients with tyrosine kinase domain mutations respond to these inhibitors and even patients that respond usually only achieve a partial remission. In addition, some base-line mutations, for example those located in exon 20 of the kinase domain, are resistant or only weakly sensitive to current anti-EGFR TKIs. The efficacy of the inhibitors is also limited in time due to, in nearly half of the cases, the appearance of cells with a second "resistance" mutation, usually T790M located in the receptor tyrosine kinase domain . An additional mechanism is the activation, either at baseline or acquired, of c-Met over-expression. Afatinib (BIBW 2992, Boehringer Ingelheim GmbH), an irreversible dual inhibitor of EGFR and HER2 kinases, retains some activity in tumors with T790M mutations although at doses that are a log higher than what is needed for cancers with only a sensitizing mutation . Afatinib is currently being evaluated in phase III trials [13–17].
The chimerical IgG1 mAb cetuximab (ERBITUX, ImClone Systems Incorporated, New York, NY, USA and Bristol-Myers Squibb Company, Princeton, NJ, USA) is the most comprehensively studied anti-EGFR antibody. By blocking the ligand-receptor interaction, cetuximab down-regulates EGFR signaling, thereby inhibiting cell proliferation, apoptosis, and angiogenesis . Cetuximab in combination with chemotherapy has been approved by the FDA for the treatment of metastatic colorectal cancer (CRC) and in combination with radiotherapy or a platinum derivative for the treatment of locally advanced head and neck cancer (HNC) [18, 19]. Cetuximab has modest activity as a single agent as well as in combination with docetaxel in patients with advanced, chemotherapy-refractory NSCLC . A multinational, multicentre, open-label, phase-III trial has shown that addition of cetuximab to platinum-based chemotherapy improved outcome for patients with advanced NSCLC . However, the effect is small and no clear predictive biomarker has been identified.
The limitations of the clinical results obtained with single agent EGFR TKIs or cetuximab justify the investigation of additional therapeutic strategies, including enhanced targeting of the EGFR. RNA interference (RNAi), has been extensively explored in recent years in many targets. The ability of small interference RNA (siRNA) sequences to modulate gene expression has provided a powerful tool with which to study gene function and is being explored in clinical trials [22, 23]. However, the combined use of RNAi and other types of EGFR targeting has not been explored.
In the current study we investigated whether the combination of EGFR inhibitory agents with EGFR-specific siRNA increases the therapeutic efficacy. To this end, we have examined the effects of either treatment alone versus the combination, in a set of lung cancer cell lines differing in their genomic status.
Cell lines and reagents
Relevant genotypic changes in the NSCLC cell lines studied
Exon 19 deletion
Exon 19 deletion
Exon 21 L858R + exon 20 T790M
The EGFR specific siRNA designed by Invitrogen (5' GCAAAGUGUGUAACGGAAUAGGUAU 3') targets a sequence starting at nucleotide 1247 and lying at the junction of exon 8 and 9 (ref. SKU#12938-076, Invitrogen Merelbeke, Belgium) . The glyceraldehyde-3-phosphate dehydrogenase (GAPDH) positive control siRNA (used in preliminary experiments to optimize the siRNA transfection efficiency, data not shown) was also from Invitrogen (ref. SKU#12935-140 Stealth RNAi GAPDH Positive Control, Invitrogen Merelbeke, Belgium). The negative control siRNA was from Eurogentec (OR-0030-neg05, Eurogentec S.A., Liege, Belgium) and consists of a proprietary siRNA sequence not corresponding to any eukaryotic gene. Transfection was by mixing siRNA with 1.5 μl Lipofectamine™2000 (Cat. No. 11668-019, Invitrogen Merelbeke, Belgium) for a final volume of 100 μl RPMI including 10% serum but without antibiotics. The procedure was according to the manufacturer. A positive control for transfection efficiency was the "TOX" transfection control, a proprietary RNA oligonucleotide that induces cell death, and siGLO Green, a modified, fluorescent RNA duplex that localizes to the nucleus (ref. D-001630-01-02 and D-001500-01-05, Thermo Scientific Dharmacon, Blenheim, UK).
RNA isolation, RNA normalization, and reverse transcription were as described previously [32, 33]. Intron-spanning RT-PCR primers (synthesized by Eurogentec S.A., Liege, Belgium) specific for EGFR or GAPDH mRNA were based upon GenBank sequence (EGFR, GeneID: 1956, NM_005228.3, and ENSEMBL sequence: ENST00000275493; GAPDH, GeneID: 2597, NM_002046.3, and Ensembl sequence: ENSG00000111640). They were designed using the Roche LightCycler Probe Design Software v1.0 followed by BLAST analysis http://blast.ncbi.nlm.nih.gov/Blast.cgi. The primer sequences were EGFR FWD: CGAGGGCAAATACAGCTT, EGFR REV: AAATTCACCAATACCTATT, and GAPDH FWD: TGAACGGGAAGCTCACTGG, GAPDH REV TCCACCACCCTGTTGCTGTA. The reverse primers were also used in the reverse transcription step. Real-time qPCR was performed in the Roche LightCycler® 1.5 instrument with SYBR green detection and melting curve analysis, as described previously . The target mRNA abundance in each sample was normalized to its reference level as ΔCq = CqEGFR-CqGAPDH, where the Cq value is the quantification cycle number. The value ΔΔCq is the difference with a mock tranfected control. Experiments were performed in triplicate. The reduction of the EGFR mRNA level was expressed as a percentage and calculated with the formula: (1-1/2ΔΔCq) × 100 [32, 34].
Western blot analysis
After being treated with siRNA for the indicated periods, the cells were washed with PBS and lysed in a buffer containing 80 mM Tris-HCl (ph 6.8), 5% SDS, 10% glycerol, 5 mM EDTA (ph 8), 5% 2-MercaptoEthanol, 0.2% Bromophenolblue, and 1 mM phenylmethylsulfonyl fluoride. The lysates were centrifuged at 12,000 × g for 10 min at 4°C and boiled for 5 min. Twenty-five microgram protein of each sample was subjected to SDS-PAGE (8% SDS-acrylamide gel) and the separated proteins were transferred to hybond ECL nitrocellulose membranes (GE Healthcare Bio-sciences/Amersham, Diegem, Belgium) for 2 h at 100 mA. The membrane was incubated with a non-phospho-Tyr1173 EGFR antibody (1:1,000 dilution, clone 20G3, mouse monoclonal IgG1К , Bio-connect, Huissen, The Netherlands.) or a β-actin antibody (ref. A1978 AC-15 1:2,000 dilution, Sigma-Aldrich N.V. Bornem, Belgium). Primary antibodies were detected with an HRP-conjugated secondary antibody (1:4,000 dilution, ECL Anti-mouse IgG Peroxidse linked Na 931, GE Healthcare Bio-sciences/Amersham, Diegem, Belgium) and finally the membranes were subjected to chemiluminescence detection assay (ECL Plus Western Blotting Detection Reagents, GE Healthcare Bio-sciences/Amersham, Diegem, Belgium). Experiments were repeated in triplicate.
Cell growth was assessed using a colorimetric tetrazolium (MTS) assay (CellTiter96 AQueous One Solution Cell Proliferation Assay G3580, Promega, Madison, WI, USA). The protocol was as follows: siRNAs, gefitinib, erlotinib, afatinib, or cetuximab were added to 96 well plates at increasing concentrations and incubated at 37°C for up to 72 h (96 h for siRNA) for single treatments. For the siRNA/TKI/antibody combinations, the agents were added to the cells first, and 24 h later the cells were transfected with EGFR siRNA in the same wells and incubated for another 48 h, because siRNA transfection efficiency is influenced by the agents if performed at the same time. Following addition of 20 μl of MTS reagent to each well, the plates were incubated for 2 h at 37°C in a humidified 5% CO2 atmosphere, and the absorbance at 490 nm was recorded using a 96-well microplate reader (Scientific Multiskan MK3, Thermo Finland). All assays were performed in triplicate. The results were the mean of six wells and expressed as the ratio of the absorbance of siRNA and/or agent treated wells/absorbance of mock control ×100.
To further confirm the data from the above MTS assay, cell viability was detected by fluorimetric detection of resorufin (CellTiter-Blue Cell Viability Assay, G8080, Promega, Madison, WI, USA). The procedure was according to the manufacturer. The treatments and controls were as mentioned above. Fluorimetry (ex: 560 nm/em: 590 nm) was using an FL600 fluorescence plate reader (Bio-Tek, Winooski, Vermont, USA). All assays were performed in triplicate and each time six individual wells were used. Fluorescence data are expressed as the fluorescence of treated sample/mock control ×100.
Caspase-3/7 activity detection
Caspase-3/7 activity was measured using a synthetic rhodamine labeled caspase-3/7 substrate (Apo-ONE® Homogeneous Caspase-3/7 Assay, G7790, Promega, Madison, WI, USA) performed immediately after the detection of cell viability (described above) on the same wells, according to the instructions of the manufacturer. After incubation at room temperature for 60 min, the fluorescence of each well was measured (ex: 499 nm/em: 512 nm), using a FL600 fluorescence plate reader (Bio-Tek, Winooski, Vermont, USA). Caspase-3/7 activity is expressed as fluorescence of treated sample/mock control×100.
Fluorescent microscopy evaluation of cell apoptosis and morphology
The effects of EGFR siRNA and different agents on apoptosis and nuclear morphology in the cells were assessed by Hoechst 33342 (Sigma-Aldrich N.V. Bornem, Belgium) and propidium iodide (PI, Sigma-Aldrich N.V. Bornem, Belgium) double fluorescent chromatin staining. In brief, after single or dual treatment of siRNA and/or agents, cells were washed with ice-cold PBS and stained 15 min with Hoechst 33342 (1 mg/ml) and PI (1 mg/ml), and observed under an advanced fluorescence microscope (ZEISS Axiovert 25, Zaventem, Belgium). Apoptosis and nuclear morphology were identified by condensation of nuclear chromatin and its fragmentation. This system determines the absolute number of viable cells (Hoechst 33342 positive/PI negative), early apoptotic cells (Hoechst 33342 positive/PI negative with blue fragmentations in the cells), late apoptotic cells (Hoechst 33342 positive/PI positive, with red fragmentations in the cells), necrotic cells (PI positive), and debris signals. Viable, apoptotic, and necrotic cells were counted in 10 different fields under the 200 × vision in each well in three independent experiments by two persons and the average result was compared to the mock control. Apoptotic cell numbers from different treatments were compared by being normalized to their viable cell numbers.
SPSS19.0 was used for statistical analysis. Results were representative of three independent experiments unless stated otherwise. Values were presented as the mean ± standard deviation (SD). One-way Analysis of Variance (ANOVA) test was used to analyze significance between groups. The least significant difference (LSD) method of multiple comparisons with parental and control group was applied when the probability for ANOVA was statistically significant. Statistical significance was determined at a P < 0.05 level. In the analysis of additivity and synergism, the theoretical zero-interaction (exactly additive) dose-response curve for each siRNA + drug combination was calculated by applying the Bliss independence criterion [35, 36]. Determination of possible synergy was also assessed by the Biosoft CalcuSyn program (Ferguson, MO, USA). The combination index (CI) was used to express synergism (CI < 1), additive effect (CI = 1), or antagonism (CI > 1) .
Effects of EGFR-specific siRNA on target expression and malignant phenotype
Targeting EGFR with kinase inhibitors alone
The effect of adding an EGFR specific siRNA to either EGFR TKIs or to cetuximab
The use of EGFR TKIs is a clinically validated therapeutic option in NSCLC, especially for those tumors that harbor a sensitizing EGFR kinase domain mutation. However, single agent TKI treatment does not completely abrogate the oncogenic action of the receptor on cell growth and apoptosis induction. Furthermore, initial responders with mutant EGFR invariably develop secondary resistance to first generation TKIs [4, 39, 40]. Several strategies are being investigated for improving this therapeutic efficacy, by either combining EGFR TKI with other agents aimed at inhibiting other growth factor pathways that are responsible for EGFR TKI resistance, such as over-expressed c-Met. Another strategy is to target the EGFR with other agents that can suppress the oncogenic function, independent of the type of mutation. An example is cetuximab. Recently, the addition of cetuximab to afatinib has yielded impressive results in the treatment of EGFR reversible TKI resistant lung cancer due to T790M mutation .
EGFR-specific siRNAs may be good candidates for cancer therapy because of their specificity, efficiency, and endurance in gene-specific silencing and ability to suppress EGFR expression independent of the mutation status of the gene. Currently, there are only a few reports on the biological effects of EGFR siRNAs on lung cancer cells [31, 42–45]. Sordella et al.  used a commercial EGFR wild-type siRNA pool that effectively induced the apoptotic enzyme caspase 3 at 96 h post transfection. The siRNA treatment also suppressed viability in H1975 cells expressing a T790M mutant EGFR and H1650 cells harboring a downstream PTEN mutation, but not in H358 cells that are wild-type for EGFR. In the present study, we have shown that an EGFR specific siRNA is very effective at suppressing the expression of EGFR in all cell lines tested, independent of the EGFR mutation status. We have also shown that all cell lines were variably inhibited in their growth by the siRNA and that the siRNA induced apoptosis in a dose- and time-dependent manner, upon transfection with siRNAs targeting wild type EGFR. Our results are partly in discordance with the data of Sordella et al. who, albeit using different siRNA sequences (commercially from Dharmacon, the concentration of siRNA was not reported) and detecting assays, found no biological effects in wild-type cells. These differences might reside in the respective concentration of the siRNAs used and the ability of the siRNAs to suppress gene expression which was high and uniform across cell lines in our experiments. Our results are in line with the report of Rothenberg et al. , which showed that lentivirus-based shRNA constructs targeting wild-type EGFR mRNA could promote cell death. Furthermore, a reduction in cell viability was observed in EGFR wild-type cells by Yamanaka et al.  who studied the effect of an EGFR siRNA (5'-GUCAGCCUGAACAUAACAU-3'), in different set of lung adenocarcinoma cell lines harboring a spectrum of EGFR wild-type, mutant, and KRAS mutant cell lines (PC-9 [EGFR 15-bp exon 19 deletion]; H3255 [EGFR L858R]; HT-1 [wt EGFR and wt KRAS]; 11-18 [wt EGFR and wt KRAS]; LK87 [KRAS G12D]; A549 [KRAS G12S]).
Although all cell lines tested in the present study were sensitive to our EGFR siRNA, some differences were noted. First of all, the differential sensitivity towards inhibition of cell growth versus apoptosis induction was not the same. The effect of an siRNA upon important aspects of the malignant phenotype, cell growth, and survival is a measure of the specific amplitude of the oncogenic potency and quality of the different mutations. The H1650 and HCC827 cell lines with an exon 19 deletion were the most sensitive, both for growth inhibition and apoptosis induction, confirming that the exon 19 mutation is the most oncogenic and addictive. H1650 cells have been described as resistant to TKIs due the loss of a functional PTEN suppressor . Our results indicate that the EGFR mutation in H1650 cells at least partially bypasses the PTEN deficiency in driving cell growth and survival and that such a downstream mutation does not confer an absolute resistance to EGFR inhibition. To the contrary, upon siRNA treatment, this cell line was the second most sensitive to both growth and apoptosis induction. The lesser sensitivity of H1975 cells to EGFR siRNA treatment despite an equally high inhibition of EGFR protein expression indicates that the EGFR carrying a T790M mutation in combination with an exon 21 mutation is a less potent driver of cell growth and survival, which could also help to explain the clinical resistance to TKI inhibition of that receptor. Our siRNA results also confirm that in EGFR wild-type cells the receptor contributes the least to the malignant phenotype if at all, especially for cell survival. While there were anti-proliferative effects in the H292 cell line with a wild-type status, this cell line was relatively resistant to apoptosis induction. This is in concordance with the clinical experience that such cancers do not really benefit from TKI treatment. The most puzzling of our results are in the H358 cell line that has a wild-type EGFR receptor and carries a homozygous KRAS mutation that normally subverts the signaling emanating from the EGFR and creates resistance to inhibition of the receptor with TKIs or monoclonal antibodies [46, 47]. In our experiments this cell line was the most sensitive to apoptosis induction and growth inhibition by siRNA EGFR inhibition. This result could not be explained by a higher EGFR mRNA knockdown in this cell line. H358 cells were found to be "KRAS-addicted" cells in which ablation of KRAS expression by shRNA interference results in apoptosis induction . Inhibition of growth by EGFR siRNA has also been observed in KRAS mutant cell lines A549 and LK87 . Our hypothesis is that the strong reduction of EGFR induced by EGFR-specific RNA interference, also induces a large depletion of GRB2-SOS complexes necessary to load GTP into normal or mutant KRAS and hence interferes with KRAS signaling. However, there are other, non-mutually exclusive possibilities. H358 cells were found to secrete increased levels of the EGFR ligand amphiregulin . Knocking down EGFR expression would interrupt the amphiregulin/EGFR positive feedback loop and this could induce apoptosis. Thirdly, H358 cells were found to have a high ErbB3 expression , and since EGFR links to PI3K signaling via ErbB3, the PI3/AKT pathway may also be a major source of malignant growth in these cells (in addition to KRAS). The removal of PI3K/AKT signals by EGFR RNAi might then also lead to apoptosis. Moreover, others have reported observations that might point in the same direction as the present study: Sunaga et al.  found that cell survival is not much affected by KRAS knockdown in KRAS mutant NSCLC cell lines and hypothesized that a feedback signal to EGFR and Akt leads to increased stimulation. An additional mechanism for the observed effect might be an off-target effect of erlotinib on the Janus kinase 2 (JAK2). Erlotinib was shown to decrease phosphorylation of JAK2 and STAT-5 in EGFR-negative myelodysplastic syndrome (MDS) cell lines KG-1  and erlotinib can disrupt signaling of the JAK2/STAT-5 pathway. JAK2 is activated by mutant p53 (or p53 deficiency) . Thus, some of the survival pathways emanating from EGFR bypass KRAS in the cell line H358, and the KRAS mutation is more important for resistance to proliferation and less for apoptosis induction. Our and others' results suggest that the presence of a KRAS mutation (or other unknown alterations in these cells) could render H358 cells dependent on EGFR signaling and that EGFR would be a candidate therapeutic target in such cancers. In the current work we have explored the effects of a near maximal elimination of EGFR using siRNA. Although our experiments do provide an estimate of the relative oncogenic potency of the various EGFR mutations and downstream mutations, currently we do not know whether it will be possible to attain similar concentrations of a therapeutic equivalent of our siRNA in vivo and in patients and thus obtain similar efficacy.
It is within that window of a maximal effect of EGFR inhibition that we have to analyze the results with TKI or cetuximab inhibition, which are strikingly different. The effect of TKI inhibition on the malignant phenotype is indeed the integration of several variables: the oncogenic potency of the targeted receptor, the significance of the kinase activity to this oncogenic potency, the variable sensitivity of the receptor to kinase inhibitors and the relative potency of kinase inhibitors to shut down this enzymatic activity. The action of monoclonal antibodies is even more complex and more difficult to relate to the mutational status of the receptor. By analogy to what is observed in the clinical studies, the exon 19 deletion HCC827 cell line conferred by far the highest sensitivity to TKI which is consistent with earlier reports [4, 29, 39, 42, 52–55]. This is also consistent with the high dependency of this cell line on this mutant receptor for cell growth and survival in our siRNA experiments. Comparatively, all other cell lines are to be considered to be relatively resistant to TKI inhibition. The striking difference with the siRNA results for the two cell lines with downstream TKI resistance mutations (PTEN and KRAS) indicates that the kinase activity of the receptor is not the sole mediator of the oncogenic activity of EGFR, although we observed some reflection of the siRNA results in the KRAS mutant H358 cells, especially with higher concentrations of erlotinib with regard to apoptosis induction. None of the cell lines had a relevant sensitivity to cetuximab alone under 10% FBS culture condition, and even the TKI sensitive cell line HCC827 cells showed limited response. This might be explained by the absence of an oncogenic significance of the wild-type receptor and insensitivity of mutant receptors to inhibition by monoclonal antibodies. Activating mutations indeed confer hypersensitivity to TKIs, but not necessarily to inhibition by monoclonal antibodies . The failure to detect a significant activity for cetuximab agrees with the absence of a significant activity as single agent or very modest added benefit in clinical lung cancer in association with chemotherapy .
Although EGFR is clearly a valid target in NSCLC treatment, the efficacy demonstrated by EGFR-targeted agents is not maximal as shown in preclinical models and more recently in clinical trials [40, 41]. One approach to improve responsiveness to EGFR inhibitors may be to simultaneously target multiple HER family members. Afatinib is currently the most advanced compound in this class. Afatinib is an irreversible EGFR/HER2 inhibitor, with activity against wild-type and mutant forms of EGFR . Afatinib was more potent than gefitinib, erlotinib, and lapatinib in inducing the cell death of NSCLC cell lines, including those harboring wild-type EGFR, and the erlotinib-resistant T790M mutation . It was also found in the present study (Figure 4) that the molar potency of afatinib against these cells was significantly higher than either gefitinib or erlotinib. HCC827 cells harboring the activating E746_A750 deletion were highly sensitive to afatinib, whereas other NSCLC cell lines were moderately sensitive, which is in agreement with other reports [57, 58]. The activity against the resistance mutation T790M and cell lines with downstream resistance mechanisms was, however, only slightly better than the reversible TKIs.
The several EGFR-targeting approaches differ in action mechanisms. TKIs compete with ATP to bind to the EGFR kinase, hence inhibiting EGFR autophosphorylation and activation of downstream signaling. Anti-EGFR antibodies prevent receptor dimerization and hence activation . However, none of these agents alone does maximally suppress EGFR signaling or the effect of mutant EGFR in the malignant phenotype, as also shown in our experiments. The combination of cetuximab with the different TKI has already been tested [60, 61]. The in vitro and in vivo results showed that the combined treatment can augment the potency of EGFR signaling inhibition. Ramalingam et al.  used a combination of cetuximab and gefitinib for patients with advanced/metastatic lung cancer who were previously treated with platinum-based chemotherapy. It was concluded that dual inhibition is feasible and safe, and may have modest activity in advanced/metastatic NSCLC. The combination of afatinib and cetuximab can even overcome resistance due to the T790M mutation both preclinically  as well as clinically . In the present study, the combined treatment of EGFR siRNA and TKIs or antibody achieved increased tumor cell growth suppression (about 30% more at the most) (Figures 5, 6, 7, 8, and 9) in all the five NSCLC cell lines and increased apoptosis as high as by 100% (Figures 10 and 11). The effect with the different agents in the different cell lines was additive, not synergistic, as calculated by a combination index (CalcuSyn software). Again, the differential sensitivity of the cell lines to the combination mimicked their sensitivity to TKI alone: the cell lines that demonstrated the most sensitivity to siRNA had the largest effect from the combination, including the cell lines with downstream TKI-resistance mutations (which also in this context displayed the highest sensitivity) or the T790M mutation. The least added effect was seen with afatinib associated to EGFR siRNA in the cell line with the TKI sensitive exon 19 deletion mutation, in which afatinib alone is already highly active at very low molar concentrations.
We conclude that RNA interference by siRNA oligonucleotides should be further explored and developed as a therapeutic modality in the treatment of EGFR mutant lung cancer and also including KRAS mutant lung cancer, and lung cancers containing the resistance mutations T790M or downstream pathway activation such as PTEN inactivation. As already mentioned, it is not known whether the concentration of siRNAs or an equivalent of this used in the present study will be achievable in vivo and in the clinic. EGFR siRNAs or a similar technology that eliminates the receptor protein physically from the cancer cell could help to improve the treatment results in difficult to treat lung cancers. Methods of in vivo siRNA delivery are currently being researched, and some reports have already described the systemic use of siRNA in cancer patients . The most appealing small molecule to test in a combination strategy would be afatinib, the irreversible EGFR/HER2 inhibitor.
This study was supported by grants of the National Cancer Plan Belgium (Grant NKP-29-011), the Stichting Tegen Kanker, Belgium, the Chinese Scholarship Council (CSC), and the Vrije Universiteit Brussel (VUB) PhD scholarship. The authors thank Goele Van Hassel for technical assistance.
- Pfister DG, Johnson DH, Azzoli CG, Sause W, Smith TJ, Baker S, Olak J, Stover D, Strawn JR, Turrisi AT, Somerfield MR: American Society of Clinical Oncology treatment of unresectable non-small-cell lung cancer guideline: update 2003. J Clin Oncol. 2004, 22: 330-353.View ArticlePubMedGoogle Scholar
- Rosell R, Gervais R, Vergnenegre A, Massuti B, Felip E, Cardenal F, Garcia Gomez R, Pallares C, Sanchez JM, Porta R, Cobo M, Di Seri M, Garrido Lopez P, Insa A, De Marinis F, Corre R, Carreras M, Carcereny E, Taron M, Paz-Ares LG: Erlotinib versus chemotherapy (CT) in advanced non-small cell lung cancer (NSCLC) patients (p) with epidermal growth factor receptor (EGFR) mutations: Interim results of the European Erlotinib Versus Chemotherapy (EURTAC) phase III randomized trial. J Clin Oncol. 2011, 29: s1.View ArticleGoogle Scholar
- Mok TS, Wu YL, Thongprasert S, Yang CH, Chu DT, Saijo N, Sunpaweravong P, Han B, Margono B, Ichinose Y, Nishiwaki Y, Ohe Y, Yang JJ, Chewaskulyong B, Jiang H, Duffield EL, Watkins CL, Armour AA, Fukuoka M: Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med. 2009, 361: 947-957. 10.1056/NEJMoa0810699.View ArticlePubMedGoogle Scholar
- Pao W, Miller VA, Politi KA, Riely GJ, Somwar R, Zakowski MF, Kris MG, Varmus H: Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med. 2005, 2: e73-10.1371/journal.pmed.0020073.View ArticlePubMedPubMed CentralGoogle Scholar
- Harari PM, Allen GW, Bonner JA: Biology of interactions: antiepidermal growth factor receptor agents. J Clin Oncol. 2007, 25: 4057-4065. 10.1200/JCO.2007.11.8984.View ArticlePubMedGoogle Scholar
- Mendelsohn J, Baselga J: Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer. J Clin Oncol. 2003, 21: 2787-2799. 10.1200/JCO.2003.01.504.View ArticlePubMedGoogle Scholar
- Zhou S, Ren S, Yan L, Zhang L, Tang L, Zhang J, Zhou C: Clinical efficacy of erlotinib in patients previously treated for advanced non-small cell lung cancer. Respirology. 2009, 14: 709-715. 10.1111/j.1440-1843.2009.01564.x.View ArticlePubMedGoogle Scholar
- Felip E, Rojo F, Reck M, Heller A, Klughammer B, Sala G, Cedres S, Peralta S, Maacke H, Foernzler D, Parera M, Möcks J, Saura C, Gatzemeier U, Baselga J: A phase II pharmacodynamic study of erlotinib in patients with advanced non-small cell lung cancer previously treated with platinum-based chemotherapy. Clin Cancer Res. 2008, 14: 3867-3874. 10.1158/1078-0432.CCR-07-5186.View ArticlePubMedGoogle Scholar
- Milton DT, Azzoli CG, Heelan RT, Venkatraman E, Gomez JE, Kris MG, Krug LM, Pao W, Rizvi NA, Dunne M, Miller VA: A phase I/II study of weekly high-dose erlotinib in previously treated patients with nonsmall cell lung cancer. Cancer. 2006, 107: 1034-1041. 10.1002/cncr.22088.View ArticlePubMedGoogle Scholar
- Shepherd FA, Rodrigues Pereira J, Ciuleanu T, Tan EH, Hirsh V, Thongprasert S, Campos D, Maoleekoonpiroj S, Smylie M, Martins R, van Kooten M, Dediu M, Findlay B, Tu D, Johnston D, Bezjak A, Clark G, Santabárbara P, Seymour L, National Cancer Institute of Canada Clinical Trials Group: Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med. 2005, 353: 123-132. 10.1056/NEJMoa050753.View ArticlePubMedGoogle Scholar
- Kelly K, Chansky K, Gaspar LE, Albain KS, Jett J, Ung YC, Lau DH, Crowley JJ, Gandara DR: Phase III trial of maintenance gefitinib or placebo after concurrent chemoradiotherapy and docetaxel consolidation in inoperable stage III non-small-cell lung cancer: SWOG S0023. J Clin Oncol. 2008, 26: 2450-2456. 10.1200/JCO.2007.14.4824.View ArticlePubMedGoogle Scholar
- Giaccone G, Wang Y: Strategies for overcoming resistance to EGFR family tyrosine kinase inhibitors. Cancer Treat Rev. 2011, 37: 456-464.PubMedPubMed CentralGoogle Scholar
- Yap TA, Vidal L, Adam J, Stephens P, Spicer J, Shaw H, Ang J, Temple G, Bell S, Shahidi M, Uttenreuther-Fischer M, Stopfer P, Futreal A, Calvert H, de Bono JS, Plummer R: Phase I trial of the irreversible EGFR and HER2 kinase inhibitor BIBW 2992 in patients with advanced solid tumors. J Clin Oncol. 2010, 28: 3965-3972. 10.1200/JCO.2009.26.7278.View ArticlePubMedGoogle Scholar
- Spicer JF, Rudman SM: EGFR inhibitors in non-small cell lung cancer (NSCLC): the emerging role of the dual irreversible EGFR/HER2 inhibitor BIBW 2992. Target Oncol. 2010Google Scholar
- Minkovsky N, Berezov A: BIBW-2992, a dual receptor tyrosine kinase inhibitor for the treatment of solid tumors. Curr Opin Investig Drugs. 2008, 9: 1336-1346.PubMedGoogle Scholar
- Eskens FA, Mom CH, Planting AS, Gietema JA, Amelsberg A, Huisman H, van Doorn L, Burger H, Stopfer P, Verweij J, de Vries EG: A phase I dose escalation study of BIBW 2992, an irreversible dual inhibitor of epidermal growth factor receptor 1 (EGFR) and 2 (HER2) tyrosine kinase in a 2-week on, 2-week off schedule in patients with advanced solid tumours. Br J Cancer. 2008, 98: 80-85. 10.1038/sj.bjc.6604108.View ArticlePubMedGoogle Scholar
- Schutze C, Dorfler A, Eicheler W, Zips D, Hering S, Solca F, Baumann M, Krause M: Combination of EGFR/HER2 tyrosine kinase inhibition by BIBW 2992 and BIBW 2669 with irradiation in FaDu human squamous cell carcinoma. Strahlenther Onkol. 2007, 183: 256-264. 10.1007/s00066-007-1696-z.View ArticlePubMedGoogle Scholar
- Griffin S, Walker S, Sculpher M, White S, Erhorn S, Brent S, Dyker A, Ferrie L, Gilfillan C, Horsley W, Macfarlane K, Thomas S: Cetuximab plus radiotherapy for the treatment of locally advanced squamous cell carcinoma of the head and neck. Health Technol Assess. 2009, 13: s49-s54.Google Scholar
- Bonner JA, Harari PM, Giralt J, Azarnia N, Shin DM, Cohen RB, Jones CU, Sur R, Raben D, Jassem J, Ove R, Kies MS, Baselga J, Youssoufian H, Amellal N, Rowinsky EK, Ang KK: Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med. 2006, 354: 567-578. 10.1056/NEJMoa053422.View ArticlePubMedGoogle Scholar
- Hanna N, Lilenbaum R, Ansari R, Lynch T, Govindan R, Janne PA, Bonomi P: Phase II trial of cetuximab in patients with previously treated non-small-cell lung cancer. J Clin Oncol. 2006, 24: 5253-5258. 10.1200/JCO.2006.08.2263.View ArticlePubMedGoogle Scholar
- Pirker R, Pereira JR, Szczesna A, von Pawel J, Krzakowski M, Ramlau R, Vynnychenko I, Park K, Yu CT, Ganul V, Roh JK, Bajetta E, O'Byrne K, de Marinis F, Eberhardt W, Goddemeier T, Emig M, Gatzemeier U, FLEX Study Team: Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial. Lancet. 2009, 373: 1525-1531. 10.1016/S0140-6736(09)60569-9.View ArticlePubMedGoogle Scholar
- Burnett JC, Rossi JJ, Tiemann K: Current progress of siRNA/shRNA therapeutics in clinical trials. Biotechnol J. 2011, 6: 1130-46. 10.1002/biot.201100054.View ArticlePubMedPubMed CentralGoogle Scholar
- Hickerson RP, Leachman SA, Pho LN, Gonzalez-Gonzalez E, Smith FJ, McLean WH, Contag CH, Leake D, Milstone LM, Kaspar RL: Development of quantitative molecular clinical end points for siRNA clinical trials. J Invest Dermatol. 2011, 131: 1029-1036. 10.1038/jid.2010.372.View ArticlePubMedGoogle Scholar
- Giovannetti E, Lemos C, Tekle C, Smid K, Nannizzi S, Rodriguez JA, Ricciardi S, Danesi R, Giaccone G, Peters GJ: Molecular mechanisms underlying the synergistic interaction of erlotinib, an epidermal growth factor receptor tyrosine kinase inhibitor, with the multitargeted antifolate pemetrexed in non-small-cell lung cancer cells. Mol Pharmacol. 2008, 73: 1290-1300. 10.1124/mol.107.042382.View ArticlePubMedGoogle Scholar
- Janmaat ML, Rodriguez JA, Gallegos-Ruiz M, Kruyt FA, Giaccone G: Enhanced cytotoxicity induced by gefitinib and specific inhibitors of the Ras or phosphatidyl inositol-3 kinase pathways in non-small cell lung cancer cells. Int J Cancer. 2006, 118: 209-214. 10.1002/ijc.21290.View ArticlePubMedGoogle Scholar
- Alemany R, Ruan S, Kataoka M, Koch PE, Mukhopadhyay T, Cristiano RJ, Roth JA, Zhang WW: Growth inhibitory effect of anti-K-ras adenovirus on lung cancer cells. Cancer Gene Ther. 1996, 3: 296-301.PubMedGoogle Scholar
- Chenau J, Michelland S, de Fraipont F, Josserand V, Coll JL, Favrot MC, Seve M: The cell line secretome, a suitable tool for investigating proteins released in vivo by tumors: application to the study of p53-modulated proteins secreted in lung cancer cells. J Proteome Res. 2009, 8: 4579-4591. 10.1021/pr900383g.View ArticlePubMedGoogle Scholar
- Sos ML, Koker M, Weir BA, Heynck S, Rabinovsky R, Zander T, Seeger JM, Weiss J, Fischer F, Frommolt P, Michel K, Peifer M, Mermel C, Girard L, Peyton M, Gazdar AF, Minna JD, Garraway LA, Kashkar H, Pao W, Meyerson M, Thomas RK: PTEN loss contributes to erlotinib resistance in EGFR-mutant lung cancer by activation of Akt and EGFR. Cancer Res. 2009, 69: 3256-3261. 10.1158/0008-5472.CAN-08-4055.View ArticlePubMedPubMed CentralGoogle Scholar
- Choi YJ, Rho JK, Jeon BS, Choi SJ, Park SC, Lee SS, Kim HR, Kim CH, Lee JC: Combined inhibition of IGFR enhances the effects of gefitinib in H1650: a lung cancer cell line with EGFR mutation and primary resistance to EGFR-TK inhibitors. Cancer Chemother Pharmacol. 2010, 66: 381-388. 10.1007/s00280-009-1174-7.View ArticlePubMedGoogle Scholar
- Shimamura T, Lowell AM, Engelman JA, Shapiro GI: Epidermal growth factor receptors harboring kinase domain mutations associate with the heat shock protein 90 chaperone and are destabilized following exposure to geldanamycins. Cancer Res. 2005, 65: 6401-6408. 10.1158/0008-5472.CAN-05-0933.View ArticlePubMedGoogle Scholar
- Tang Z, Du R, Jiang S, Wu C, Barkauskas DS, Richey J, Molter J, Lam M, Flask C, Gerson S, Dowlati A, Liu L, Lee Z, Halmos B, Wang Y, Kern JA, Ma PC: Dual MET-EGFR combinatorial inhibition against T790M-EGFR-mediated erlotinib-resistant lung cancer. Br J Cancer. 2008, 99: 911-922. 10.1038/sj.bjc.6604559.View ArticlePubMedPubMed CentralGoogle Scholar
- Chen G, Kronenberger P, Teugels E, De Greve J: Influence of RT-qPCR primer position on EGFR interference efficacy in lung cancer cells. Biol Proced Online. 2011, 13: 1-10.1186/1480-9222-13-1.View ArticleGoogle Scholar
- Chen G, Kronenberger P, Umelo IA, Teugels E, De Greve J: Quantification of epidermal growth factor receptor T790M mutant transcripts in lung cancer cells by real-time reverse transcriptase-quantitative polymerase chain reaction. Anal Biochem. 2010, 398: 266-268. 10.1016/j.ab.2009.11.034.View ArticlePubMedGoogle Scholar
- Livak KJ, Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods. 2001, 25: 402-408. 10.1006/meth.2001.1262.View ArticlePubMedGoogle Scholar
- Suhnel J: Zero interaction response surfaces for combined-action assessment. Food Chem Toxicol. 1996, 34: 1151-1153. 10.1016/S0278-6915(97)00087-2.View ArticlePubMedGoogle Scholar
- Koivusalo R, Krausz E, Helenius H, Hietanen S: Chemotherapy compounds in cervical cancer cells primed by reconstitution of p53 function after short interfering RNA-mediated degradation of human papillomavirus 18 E6 mRNA: opposite effect of siRNA in combination with different drugs. Mol Pharmacol. 2005, 68: 372-382.PubMedGoogle Scholar
- Chou TC: Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies. Pharmacol Rev. 2006, 58: 621-681. 10.1124/pr.58.3.10.View ArticlePubMedGoogle Scholar
- Tabernero J, Ciardiello F, Rivera F, Rodriguez-Braun E, Ramos FJ, Martinelli E, Vega-Villegas ME, Roselló S, Liebscher S, Kisker O, Macarulla T, Baselga J, Cervantes A: Cetuximab administered once every second week to patients with metastatic colorectal cancer: a two-part pharmacokinetic/pharmacodynamic phase I dose-escalation study. Ann Oncol. 2010, 21: 1537-1545. 10.1093/annonc/mdp549.View ArticlePubMedGoogle Scholar
- Kobayashi S, Ji H, Yuza Y, Meyerson M, Wong KK, Tenen DG, Halmos B: An alternative inhibitor overcomes resistance caused by a mutation of the epidermal growth factor receptor. Cancer Res. 2005, 65: 7096-7101. 10.1158/0008-5472.CAN-05-1346.View ArticlePubMedGoogle Scholar
- Regales L, Gong Y, Shen R, de Stanchina E, Vivanco I, Goel A, Koutcher JA, Spassova M, Ouerfelli O, Mellinghoff IK, Zakowski MF, Politi KA, Pao W: Dual targeting of EGFR can overcome a major drug resistance mutation in mouse models of EGFR mutant lung cancer. J Clin Invest. 2009, 119: 3000-3010.PubMedPubMed CentralGoogle Scholar
- Janjigian YY, Groen HJ, Horn L, Smit EF, Fu Y, Wang F, Shahidi M, Denis LJ, Pao W, Miller VA: Activity and tolerability of afatinib (BIBW 2992) and cetuximab in NSCLC patients with acquired resistance to erlotinib or gefitinib. J Clin Oncol. 2011, 29: s7525^.Google Scholar
- Engelman JA, Mukohara T, Zejnullahu K, Lifshits E, Borrás AM, Gale CM, Naumov GN, Yeap BY, Jarrell E, Sun J, Tracy S, Zhao X, Heymach JV, Johnson BE, Cantley LC, Jänne PA: Allelic dilution obscures detection of a biologically significant resistance mutation in EGFR-amplified lung cancer. J Clin Invest. 2006, 116: 2695-2706. 10.1172/JCI28656.View ArticlePubMedPubMed CentralGoogle Scholar
- Rothenberg SM, Engelman JA, Le S, Riese DJ, Haber DA, Settleman J: Modeling oncogene addiction using RNA interference. Proc Natl Acad Sci USA. 2008, 105: 12480-12484. 10.1073/pnas.0803217105.View ArticlePubMedPubMed CentralGoogle Scholar
- Sordella R, Bell DW, Haber DA, Settleman J: Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways. Science. 2004, 305: 1163-1167. 10.1126/science.1101637.View ArticlePubMedGoogle Scholar
- Yamanaka S, Gu Z, Sato M, Fujisaki R, Inomata K, Sakurada A, Inoue A, Nukiwa T, Kondo T, Horii A: siRNA targeting against EGFR, a promising candidate for a novel therapeutic application to lung adenocarcinoma. Pathobiology. 2008, 75: 2-8. 10.1159/000113789.View ArticlePubMedGoogle Scholar
- Pao W, Wang TY, Riely GJ, Miller VA, Pan Q, Ladanyi M, Zakowski MF, Heelan RT, Kris MG, Varmus HE: KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib. PLoS Med. 2005, 2: e17-10.1371/journal.pmed.0020017.View ArticlePubMedPubMed CentralGoogle Scholar
- Massarelli E, Varella-Garcia M, Tang X, Xavier AC, Ozburn NC, Liu DD, Bekele BN, Herbst RS, Wistuba II: KRAS mutation is an important predictor of resistance to therapy with epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer. Clin Cancer Res. 2007, 13: 2890-2896. 10.1158/1078-0432.CCR-06-3043.View ArticlePubMedGoogle Scholar
- Singh A, Greninger P, Rhodes D, Koopman L, Violette S, Bardeesy N, Settleman J: A gene expression signature associated with "K-Ras addiction" reveals regulators of EMT and tumor cell survival. Cancer Cell. 2009, 15: 489-500. 10.1016/j.ccr.2009.03.022.View ArticlePubMedPubMed CentralGoogle Scholar
- Sunaga N, Shames DS, Girard L, Peyton M, Larsen JE, Imai H, Soh J, Sato M, Yanagitani N, Kaira K, Xie Y, Gazdar AF, Mori M, Minna JD: Knockdown of oncogenic KRAS in non-small cell lung cancers suppresses tumor growth and sensitizes tumor cells to targeted therapy. Mol Cancer Ther. 2011, 10: 336-346. 10.1158/1535-7163.MCT-10-0750.View ArticlePubMedPubMed CentralGoogle Scholar
- Boehrer S, Adès L, Braun T, Galluzzi L, Grosjean J, Fabre C, Le Roux G, Gardin C, Martin A, de Botton S, Fenaux P, Kroemer G: Erlotinib exhibits antineoplastic off-target effects in AML and MDS: a preclinical study. Blood. 2008, 111: 2170-2180. 10.1182/blood-2007-07-100362.View ArticlePubMedGoogle Scholar
- Reid T, Jin X, Song H, Tang HJ, Reynolds RK, Lin J: Modulation of Janus kinase 2 by p53 in ovarian cancer cells. Biochem Biophys Res Commun. 2004, 321: 441-447. 10.1016/j.bbrc.2004.06.169.View ArticlePubMedGoogle Scholar
- Busser B, Sancey L, Josserand V, Niang C, Favrot MC, Coll JL, Hurbin A: Amphiregulin promotes BAX inhibition and resistance to gefitinib in non-small-cell lung cancers. Mol Ther. 2010, 18: 528-535. 10.1038/mt.2009.226.View ArticlePubMedGoogle Scholar
- Tam IY, Leung EL, Tin VP, Chua DT, Sihoe AD, Cheng LC, Chung LP, Wong MP: Double EGFR mutants containing rare EGFR mutant types show reduced in vitro response to gefitinib compared with common activating missense mutations. Mol Cancer Ther. 2009, 8: 2142-2151. 10.1158/1535-7163.MCT-08-1219.View ArticlePubMedGoogle Scholar
- Rice SD, Bush JE, Brower SL: Assessment of erlotinib in chemoresponse assay. Anticancer Res. 2009, 29: 1993-1997.PubMedGoogle Scholar
- Gadgeel SM, Ali S, Philip PA, Wozniak A, Sarkar FH: Genistein enhances the effect of epidermal growth factor receptor tyrosine kinase inhibitors and inhibits nuclear factor kappa B in nonsmall cell lung cancer cell lines. Cancer. 2009, 115: 2165-2176. 10.1002/cncr.24250.View ArticlePubMedGoogle Scholar
- Yun CH, Boggon TJ, Li Y, Woo MS, Greulich H, Meyerson M, Eck MJ: Structures of lung cancer-derived EGFR mutants and inhibitor complexes: mechanism of activation and insights into differential inhibitor sensitivity. Cancer Cell. 2007, 11: 217-227. 10.1016/j.ccr.2006.12.017.View ArticlePubMedPubMed CentralGoogle Scholar
- Li D, Ambrogio L, Shimamura T, Kubo S, Takahashi M, Chirieac LR, Padera RF, Shapiro GI, Baum A, Himmelsbach F, Rettig WJ, Meyerson M, Solca F, Greulich H, Wong KK: BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models. Oncogene. 2008, 27: 4702-4711. 10.1038/onc.2008.109.View ArticlePubMedPubMed CentralGoogle Scholar
- Takezawa K, Okamoto I, Tanizaki J, Kuwata K, Yamaguchi H, Fukuoka M, Nishio K, Nakagawa K: Enhanced anticancer effect of the combination of BIBW2992 and thymidylate synthase-targeted agents in non-small cell lung cancer with the T790M mutation of epidermal growth factor receptor. Mol Cancer Ther. 2010, 9: 1647-1656. 10.1158/1535-7163.MCT-09-1009.View ArticlePubMedGoogle Scholar
- Marshall J: Clinical implications of the mechanism of epidermal growth factor receptor inhibitors. Cancer. 2006, 107: 1207-1218. 10.1002/cncr.22133.View ArticlePubMedGoogle Scholar
- Huang S, Armstrong EA, Benavente S, Chinnaiyan P, Harari PM: Dual-agent molecular targeting of the epidermal growth factor receptor (EGFR): combining anti-EGFR antibody with tyrosine kinase inhibitor. Cancer Res. 2004, 64: 5355-5362. 10.1158/0008-5472.CAN-04-0562.View ArticlePubMedGoogle Scholar
- Matar P, Rojo F, Cassia R, Moreno-Bueno G, Di Cosimo S, Tabernero J, Guzman M, Rodriguez S, Arribas J, Palacios J, Baselga J: Combined epidermal growth factor receptor targeting with the tyrosine kinase inhibitor gefitinib (ZD1839) and the monoclonal antibody cetuximab (IMC-C225): superiority over single-agent receptor targeting. Clin Cancer Res. 2004, 10: 6487-6501. 10.1158/1078-0432.CCR-04-0870.View ArticlePubMedGoogle Scholar
- Ramalingam S, Forster J, Naret C, Evans T, Sulecki M, Lu H, Teegarden P, Weber MR, Belani CP: Dual inhibition of the epidermal growth factor receptor with cetuximab, an IgG1 monoclonal antibody, and gefitinib, a tyrosine kinase inhibitor, in patients with refractory non-small cell lung cancer (NSCLC): a phase I study. J Thorac Oncol. 2008, 3: 258-264. 10.1097/JTO.0b013e3181653d1b.View ArticlePubMedGoogle Scholar
- Davis ME, Zuckerman JE, Choi CH, Seligson D, Tolcher A, Alabi CA, Yen Y, Heidel JD, Ribas A: Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles. Nature. 2010, 464: 1067-1070. 10.1038/nature08956.View ArticlePubMedPubMed CentralGoogle Scholar
- The pre-publication history for this paper can be accessed here:http://0-www.biomedcentral.com.brum.beds.ac.uk/1741-7015/10/28/prepub
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.